| abstract |
New substituted 1-(4-amino-6,7-dialkoxyquinazolinyl)-4-cyclohexenyl derivatives of piperazine and homopiperazine, of the general formula I <IMAGE> in which R1, R2, R3, R4 and R5, which can be identical or different, denote hydrogen, straight-chain or branched alkyl groups with in each case 1 to 6 carbon atoms, cyclic aliphatic radicals with in each case 5 to 7 carbon atoms, aromatic radicals or substituted aromatic radicals, which can be monosubstituted or polysubstituted by identical or different substituents from the group comprising halogen and lower alkyl groups with in each case 1 to 4 carbon atoms in the alkyl part, or denote aralkyl radicals, furanyl radicals or thienyl radicals, or R2 and R3 together denote the group -(CH2)a-, wherein a is the number 4 or 5, or R3 and R4 together denote the group -(CH2)b-, wherein b is the number 3, 4 or 5, R6 and R7, which can be identical or different, denote alkoxy groups with 1 to 4 carbon atoms in the alkyl part, which can be straight-chain or branched, and n denotes the number 1 or 2, and tautomeric forms thereof, as well as acid addition salts and hydrates thereof, reduce the arterial blood pressure and promote blood flow in the vessels. They can be used as medicaments for the treatment of hypertension, glaucoma and cardiac insufficiency. |